Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Pharma HoldingSTU:XQJ 33 Earnings Yield (Joel Greenblatt) % is -14.35% as of Jun. 2026. GuruFocus rates STU:XQJ with a GF Score™ of 33/100 and a GF Value™ of €5.15. The stock has 4 warning signs investors should review. Among 1,008 Drug Manufacturers companies, China Pharma Holding ranks worse than 86.21% on this metric.
China Pharma Holding's Enterprise Value for the quarter that ended in Jun. 2026 was €1,089.25 Mil.
China Pharma Holding's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-3.77 Mil. China Pharma Holding's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -14.35%.
The historical rank and industry rank for China Pharma Holding's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
STU:XQJ'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -117.86 Med: -43.11 Max: -4.54
Current: -10.6
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of China Pharma Holding was -4.54%. The lowest was -117.86%. And the median was -43.11%.
STU:XQJ's Earnings Yield (Joel Greenblatt) % is ranked worse than 86.21% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.01
vs STU:XQJ: -10.60
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. China Pharma Holding's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
China Pharma Holding (STU:XQJ) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
China Pharma Holding Earnings Yield (Joel Greenblatt) % Related Terms
China Pharma Holding Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for China Pharma Holding's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding Earnings Yield (Joel Greenblatt) % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Pharma Holding Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's Earnings Yield (Joel Greenblatt) % falls into.
China Pharma Holding Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
China Pharma Holdings Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
China Pharma Holding's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.77 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -14.35% mean?
China Pharma Holding (STU:XQJ) has a Earnings Yield (Joel Greenblatt) % of -14.35% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on China Pharma Holding and its competitors. According to the industry distribution chart, China Pharma Holding ranks #869 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 86.2%.
Is China Pharma Holding's Earnings Yield (Joel Greenblatt) % too high?
China Pharma Holding's current Earnings Yield (Joel Greenblatt) % is -14.35%. Based on the distribution chart, China Pharma Holding ranks #869 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China Pharma Holding has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's Earnings Yield (Joel Greenblatt) % compare to IXHL and MRMD?
According to the Drug Manufacturers industry distribution chart, China Pharma Holding ranks #869 out of 1008 companies for Earnings Yield (Joel Greenblatt) %. This places China Pharma Holding in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.01, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on China Pharma Holding and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Pharma Holding's current Earnings Yield (Joel Greenblatt) % is -14.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
China Pharma Holding (STU:XQJ) has a current Earnings Yield (Joel Greenblatt) % of -14.35%. The stock's GF Value™ is €5.15, compared to a current price of €26.80 — trading 420.4% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -14.35%. China Pharma Holding's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For China Pharma Holding (STU:XQJ), the current Earnings Yield (Joel Greenblatt) % is -14.35% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Pharma Holding (STU:XQJ) Overvalued in 2026?
Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued.
The current stock price of €26.80 is trading 420.4% above its estimated GF Value™ of €5.15.
Key valuation signals for STU:XQJ:
Earnings Yield (Joel Greenblatt) %: -14.35%
GF Value™: €5.15 vs. price of €26.80 (420.4% above fair value)
No single metric tells the full story. See the STU:XQJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
33GF Score
Get the complete analysis for STU:XQJ
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:XQJ has been successfully added to your 
